Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
Recruiting
Observational Study
Atrial Fibrillation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 79
- Sex
- Any
- Study type
- Observational
- Participants needed
- 360 (estimated)
- Sponsor
- Tulane University School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Participants must meet the following criteria to be enrolled in the trial:
* Participants with atrial fibrillation aged 18 to 79 years old, or
* Participants aged 40 to 79 years old, at moderate or high risk for CVD as defined by the 10-year risk Atherosclerotic Cardiovascular …
Contacts